WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319702

CAS#: 495399-09-2 (free)

Description: Saroglitazar is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia. It is approved for use in India by the Drug Controller General of India. Saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). Saroglitazar is novel first in class drug which acts as a dual PPAR agonist at the subtypes α (alpha) and γ (gamma) of the peroxisome proliferator-activated receptor (PPAR). Agonist action at PPARα lowers high blood triglycerides, and agonist action on PPARγ improves insulin resistance and consequently lowers blood sugar.

Chemical Structure

CAS# 495399-09-2 (free)

Theoretical Analysis

MedKoo Cat#: 319702
Name: Saroglitazar
CAS#: 495399-09-2 (free)
Chemical Formula: C25H29NO4S
Exact Mass: 439.1817
Molecular Weight: 439.57
Elemental Analysis: C, 68.31; H, 6.65; N, 3.19; O, 14.56; S, 7.29

Price and Availability

Size Price Availability Quantity
5.0mg USD 650.0 2 Weeks
100.0mg USD 2450.0 2 Weeks
500.0mg USD 3850.0 2 Weeks
Bulk inquiry

Related CAS #: 1639792-20-3 (magnesium)   495399-09-2 (free)    

Synonym: ZYH1; ZYH-1; ZYH 1; Saroglitazar, trade name: Lipaglyn.

IUPAC/Chemical Name: (S)-2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoic acid


InChi Code: InChI=1S/C25H29NO4S/c1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20/h5-14,24H,4,15-17H2,1-3H3,(H,27,28)/t24-/m0/s1


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 439.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Deshpande A, Toshniwal H, Joshi S, Jani RH. A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy. PLoS One. 2016 Jan 20;11(1):e0146222. doi: 10.1371/journal.pone.0146222. eCollection 2016. PubMed PMID: 26789842.

2: Jain MR, Giri SR, Trivedi C, Bhoi B, Rath A, Vanage G, Vyas P, Ranvir R, Patel PR. Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect. 2015 Jun;3(3):e00136. doi: 10.1002/prp2.136. Epub 2015 May 4. PubMed PMID: 26171220; PubMed Central PMCID: PMC4492752.

3: Sosale A, Saboo B, Sosale B. Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence. Diabetes Metab Syndr Obes. 2015 Apr 15;8:189-96. doi: 10.2147/DMSO.S49592. eCollection 2015. Review. PubMed PMID: 25926748; PubMed Central PMCID: PMC4403747.

4: Shetty SR, Kumar S, Mathur RP, Sharma KH, Jaiswal AD. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients. Indian Heart J. 2015 Jan-Feb;67(1):23-6. doi: 10.1016/j.ihj.2015.02.007. Epub 2015 Feb 26. PubMed PMID: 25820046; PubMed Central PMCID: PMC4382542.

5: Ramakrishnan S. From 'Make in India' to 'Made in India': the saroglitazar story. Indian Heart J. 2015 Jan-Feb;67(1):8-10. doi: 10.1016/j.ihj.2015.02.014. Epub 2015 Mar 4. PubMed PMID: 25820041; PubMed Central PMCID: PMC4382552.

6: Joshi SR. Saroglitazar for the treatment of dyslipidemia in diabetic patients. Expert Opin Pharmacother. 2015 Mar;16(4):597-606. doi: 10.1517/14656566.2015.1009894. Review. PubMed PMID: 25674933.

7: Chatterjee S, Majumder A, Ray S. Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes. Sci Rep. 2015 Jan 9;5:7706. doi: 10.1038/srep07706. PubMed PMID: 25573251; PubMed Central PMCID: PMC4287720.

8: Munigoti SP, Harinarayan CV. Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone? Indian J Endocrinol Metab. 2014 May;18(3):283-7. doi: 10.4103/2230-8210.131134. Review. PubMed PMID: 24944919; PubMed Central PMCID: PMC4056123.

9: Pai V, Paneerselvam A, Mukhopadhyay S, Bhansali A, Kamath D, Shankar V, Gambhire D, Jani RH, Joshi S, Patel P. A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V). J Diabetes Sci Technol. 2014 Jan 16;8(1):132-141. [Epub ahead of print] PubMed PMID: 24876549; PubMed Central PMCID: PMC4390522.

10: Manoria PC, Chopra HK, Parashar SK, Dutta AL, Pinto B, Mullasari A, Prajapati S. The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies. Indian Heart J. 2013 Dec;65(6):683-90. doi: 10.1016/j.ihj.2013.10.015. Epub 2013 Nov 25. Review. PubMed PMID: 24407538; PubMed Central PMCID: PMC3905264.

11: Jani RH, Pai V, Jha P, Jariwala G, Mukhopadhyay S, Bhansali A, Joshi S. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther. 2014 Feb;16(2):63-71. doi: 10.1089/dia.2013.0253. Epub 2013 Oct 18. PubMed PMID: 24138536; PubMed Central PMCID: PMC3894674.

12: Jani RH, Kansagra K, Jain MR, Patel H. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16. doi: 10.1007/s40261-013-0128-3. PubMed PMID: 24062180; PubMed Central PMCID: PMC3824340.

13: Agrawal R. The first approved agent in the Glitazar's Class: Saroglitazar. Curr Drug Targets. 2014 Feb;15(2):151-5. PubMed PMID: 23906191.